

UC Davis

UC Davis Previously Published Works

Title

Neonatal Cytokine Profiles Associated With Autism Spectrum Disorder

Permalink

<https://escholarship.org/uc/item/9bb9f1s3>

Journal

Biological Psychiatry, 81(5)

ISSN

0006-3223

Authors

Krakowiak, Paula

Goines, Paula E

Tancredi, Daniel J

et al.

Publication Date

2017-03-01

DOI

10.1016/j.biopsych.2015.08.007

Peer reviewed



Published in final edited form as:

Biol Psychiatry. 2017 March 01; 81(5): 442–451. doi:10.1016/j.biopsych.2015.08.007.

Neonatal cytokine profiles associated with autism spectrum disorder

Paula Krakowiak^{#a,c}, Paula E. Goines^{#b}, Daniel J. Tancredi^d, Paul Ashwood^{c,e}, Robin L. Hansen^{c,f}, Irva Hertz-Picciotto^{a,c}, and Judy Van de Water^{b,c}

^aDivisions of Epidemiology and of Environmental and Occupational Health, Department of Public Health Sciences, School of Medicine, University of California, Davis

^bDivision of Rheumatology, Allergy and Clinical Immunology, Department of Internal Medicine, School of Medicine, University of California, Davis

^cMIND (Medical Investigations of Neurodevelopmental Disorders) Institute, University of California, Davis

^dDepartment of Pediatrics, School of Medicine, University of California, Davis

^eDepartment of Medical Microbiology and Immunology, School of Medicine, University of California, Davis

^fDivision of Developmental Behavioral Pediatrics, Department of Pediatrics, School of Medicine, University of California, Davis

These authors contributed equally to this work.

Abstract

Background—Autism spectrum disorder (ASD) is a complex neurodevelopmental condition that can be reliably diagnosed as early as 24 months. Immunological phenomena, including skewed cytokine production, have been observed among children with ASD. Little is known about whether immune dysregulation is present before diagnosis of ASD.

Methods—We utilized neonatal blood spots from 214 children with ASD (141 severe, 73 mild/moderate), 62 typically developing (TD), and 27 developmental delayed controls who participated in CHARGE (Childhood Autism Risks from Genetics and the Environment), a population-based case-control study. Levels of 17 cytokines/chemokines were compared across groups and in relation to developmental/behavioral domains.

Corresponding author: Judy Van de Water, Ph.D., Professor of Medicine, University of California, Davis, Division of Rheumatology, Allergy and Clinical Immunology, 451 Health Sciences Drive, Suite 6510, Davis, CA 95616-5270., Telephone: 530-752-2154, Fax: 530-754-6047, javandewater@ucdavis.edu.

FINANCIAL DISCLOSURES

All authors report no biomedical financial interests or potential conflicts of interest.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Results—Interleukin (IL)-1 β and IL-4 were independently associated with ASD vs. TD although these relationships varied by ASD symptom intensity. Elevated IL-4 associated with increased odds of severe ASD (ASD_{sev}) (odds ratio[OR]=1.40, 95% confidence interval[CI] 1.03, 1.91) whereas IL-1 β associated with increased odds of mild/moderate ASD (ASD_{mild}) (OR=3.02, 95% CI 1.43, 6.38). Additionally, IL-4 was associated with a higher likelihood of ASD_{sev} vs. ASD_{mild} (OR=1.35, 95% CI 1.04, 1.75). In male ASD cases, IL-4 was negatively associated with non-verbal cognitive ability (β =-3.63, SE=1.33, P =0.04).

Conclusions—This study is part of a growing effort to identify early biological markers for ASD. We demonstrate that peripheral cytokine profiles at birth are associated with ASD later in childhood and that cytokine profiles vary depending on ASD severity. Cytokines have complex roles in neurodevelopment, and dysregulated levels may be indicative of genetic differences and environmental exposures or their interactions that relate to ASD.

Keywords

neonatal cytokines, chemokines; autism spectrum disorder; developmental delays; bloodspot; neurodevelopment

INTRODUCTION

Autism spectrum disorder (ASD) is a neurodevelopmental disorder characterized by social deficits and restricted or stereotyped behavior patterns that manifest by age three.(1-3) The biological basis of ASD is unclear but likely involves a complex interplay between genetic susceptibility and environmental exposures.(4) There are no consistent biological markers for ASD, and diagnosis is based upon behavioral traits and developmental history.(5-7) The most consistently beneficial treatment for ASD is behavioral therapy, which is most effective when administered early in life.(8) Therefore, two major goals in autism research are characterization of biological signatures for ASD and early identification of children at risk.

Immunological factors may be involved in ASD. This includes alterations in the prenatal immune environment that may contribute to the risk of developing ASD.(9-11) Further, children diagnosed with ASD have evidence of immune dysfunction that is detected at young ages and near to diagnoses.(12-17) However, it is unclear whether these immunological differences arise in children before or after diagnosis. Resolving this issue is critical to understanding the temporal relationship between immune anomalies and the development of ASD.

Two recent studies found differences in cytokine/chemokine levels measured in newborn blood spots of children later diagnosed with ASD compared with controls.(18-20) Abdallah et al. found decreased levels of many cytokines (i.e., interferon- γ , interleukin [IL]-2, IL-4, IL-6, IL-10) in neonatal samples from children with ASD, and no differences in chemokine levels.(18, 19) In contrast, Zerbo et al. reported increased monocyte chemotactic protein (MCP)-1 and decreased Regulated upon Activation Normal T-Cell Expressed and Secreted (RANTES) in ASD cases versus controls.(20) While these studies present novel data, they are limited by lack of clinical confirmation of ASD and older diagnostic tools due to the timing of specimen collection. The current study utilizes archived neonatal dried blood spot

samples to explore whether early immunological signs, specifically cytokine profiles, are predictive of neurodevelopmental outcomes in a well-defined study population of children with a confirmed diagnosis of ASD, developmental delays (DD) without ASD, or typical development (TD).

METHODS AND MATERIALS

Participants

This study utilized neonatal blood spots archived by the State of California and obtained for a subset of 303 children (214 ASD, 27 DD, and 62 TD) enrolled in the CHARGE (Childhood Autism Risks from Genetics and the Environment) Study(21) between January 2003 and October 2005. CHARGE is an ongoing population-based case-control study investigating risk factors for neurodevelopmental disorders, with participants selected from 3 groups: ASD, DD, and TD from the general population. Eligible children were 2-5 years old, born in California, living with a biological parent who speaks English or Spanish, and residing in selected regional center catchment areas. Children were identified as described previously.(21) CHARGE protocol was approved by the institutional review boards at the University of California in Davis and Los Angeles and the State of California Committee for the Protection of Human Subjects. Written informed consent was obtained prior to participation.

Diagnostic Confirmation

Children were assessed at the UC Davis MIND (Medical Investigation of Neurodevelopmental Disorders) Institute at study enrollment (2-5 years old). Cognitive and adaptive function were evaluated in all children with Mullen Scales of Early Learning (MSEL)(22) and Vineland Adaptive Behavior Scales (VABS)(23), respectively. ASD diagnosis was confirmed with the Autism Diagnostic Interview–Revised (ADI-R)(24) and the Autism Diagnostic Observation Schedule (ADOS)(6, 25) using criteria described by Risi *et al.*(26) and in accordance with the Diagnostic and Statistical Manual of Mental Disorders–5 (DSM-5).(3) Children with ASD (n=214) were subdivided into those exhibiting severe ASD symptoms (ASD_{sev} [n=141]) and those with mild to moderate symptoms (ASD_{mild} [n=73]) using ADOS comparison scores ≥ 7 and <7 , respectively.(25)

Controls were screened for ASD using the Social Communication Questionnaire (SCQ)(27); those with SCQ ≥ 15 were evaluated with ADI-R and ADOS and reclassified if they met criteria for ASD. TD controls had no prior diagnosis of ASD or DD and composite scores ≥ 70 on both MSEL and VABS. DD controls had composite scores <70 on both MSEL and VABS.

Behavioral and Developmental Assessments

Aberrant Behavior Checklist (ABC)(28) measures maladaptive behavior using subscales: Irritability (15 items), Lethargy/Social Withdrawal (16 items), Stereotypy (7 items), and Hyperactivity (16 items). Each item is rated on a 4-point Likert scale ranging from 0 = Not at all a problem to 3 = Problem severe in degree.

Mullen Scales of Early Learning (MSEL) is a standardized assessment of cognitive development in young children and includes scales: Visual Reception (non-verbal cognitive ability), Fine Motor, Receptive Language (language comprehension), and Expressive Language (language production). Developmental quotients (DQ; [age equivalent / chronological age] × 100) were calculated for each scale and composite to overcome the floor effect.

Vineland Adaptive Behavior Scales (VABS) is a standardized assessment that measures personal and social skills needed for everyday living on these domains: Communication, Daily Living Skills, Socialization, and Motor Skills. DQs were calculated as described above.

Blood Spot Specimens

In California, capillary blood is collected at birth by heel-prick, spotted onto standardized filter paper, and tested for various disorders as part of the Genetic Disease Screening Program. The remaining specimen is stored through the California Department of Public Health.(29)

Blood Spot Elution

Three 3mm punches of each dried blood spot specimen were placed together into a single well in a 96-well plate and stored at -80°C until elution. The blood spot elution protocol is as follows: 200 μl of elution buffer (Phosphate buffered saline, 0.5% Bovine serum albumin, and protease inhibitors (Roche Complete Protease Inhibitor Cocktail, Roche Applied Science, Indianapolis, IN)) was added to each well, and plates were placed on a plate shaker overnight at 4°C . The eluates were analyzed immediately following elution.

Cytokine/Chemokine Measurement

Blood spot cytokine and chemokine levels were measured using Luminex multiplex technology. Cytokines interleukin (IL)-1 β , IL-2, IL-4, IL-5, IL-6, IL-10, IL-12, IL-13, interferon (IFN)- γ , and tumor necrosis factor (TNF)- α were measured using high sensitivity Bio-Plex Precision Pro human cytokine kits (Bio-Rad, Hercules, CA). Chemokines IL-8, MCP-1, macrophage inflammatory protein (MIP)-1 α , MIP-1 β , Eotaxin, interferon- γ induced protein (IP)-10, and RANTES were measured using Milliplex human chemokine kits according to directions (Millipore, Billerica, MA). Briefly, 25 μl of eluate was incubated with the kit beads with shaking overnight at 4°C . The beads were then washed using a vacuum manifold, and biotin-conjugated detection antibodies were added for a 1-hour incubation. After washing, the beads were incubated with streptavidin-PE for 30 minutes, the plates read on a Bio-Plex 100 (BioRad, Hercules, CA), and the signal analyzed using Bio-Plex Manager software using a 5-point standard curve. Because eluted blood spots contain rehydrated components of whole blood, including plasma and lysed cells, the cytokine/chemokine profiles are derived from both plasma and cellular sources. Total protein was measured in each eluted blood spot sample using a Pierce BCA protein assay (Rockford, IL). Cytokine/chemokine concentrations were normalized for total protein content and presented in pg/mg total protein.

Statistical Analysis

All statistical analyses were limited to 303 children with a confirmed diagnosis of ASD ($n=214$; ASD_{sev} $n=141$ and ASD_{mild} $n=73$), DD ($n=27$) or TD ($n=62$) whose blood spots were collected ≤ 48 hours of birth. Excluded from the initial sample of 459 children with blood spots were 77 children with other ($n=58$) or incomplete ($n=19$) diagnoses, and 79 children with blood collected >48 hours after delivery. Cytokine/chemokine concentrations were ln-transformed to normalize their distributions. All analyses were carried out using SAS version 9.4 (SAS Institute Inc., Cary, NC).

Multiple imputation of cytokines/chemokines with values below level of detection (LOD)—We used PROC MI with the Fully Conditional Specification (FCS) method in SAS to impute values $<LOD$ for each ln-transformed cytokine/chemokine (pg/ml eluate) separately and included the following variables: (1) ln-transformed cytokines/chemokines without missing values $<LOD$, (2) covariates: age at blood spot collection, years between sample collection and elution, birth month, gestational age, (3) child's diagnosis, and (4) the cytokine/chemokine being imputed with values $<LOD$ replaced by $LOD/2$ and adjusted for total protein (to keep imputed values in the low range of distribution). Ten imputation datasets were created in the first PROC MI step; the output dataset from the first step was used as the input dataset for the next PROC MI step (with 'by imputation' statement) to impute the next cytokine/chemokine, and so on until all values $<LOD$ were imputed. The upper bound for imputed values was restricted to the lowest detectable value of a given cytokine/chemokine but could not be set for IFN- γ , IL-10, IL-5, IL-13, IL-4, MIP-1 α , IL-6, and Eotaxin (due to convergence problems); nonetheless, there was little to no overlap between the distributions of imputed values ($<LOD$) and detectable values (Figure S1). Analyte concentrations were then exponentiated, corrected for total protein, and ln-transformed again for analysis. We performed all statistical analyses on the imputed datasets and combined the results using PROC MIANALYZE (with edf= option specifying degrees of freedom) to obtain inferences.

Principal Components Analysis (PCA)—Using imputed data, we conducted a PCA to examine the patterns of all cytokines/chemokines simultaneously in cases and controls and to visually inspect whether any clusters emerged by diagnostic group. Orthogonal rotations were performed, and only components that explained $\geq 10\%$ of total variance were retained and verified by Horn's parallel analysis.⁽³⁰⁾ Analytes with loadings <0.40 were suppressed in the final component loading matrices.

Logistic Regression Analyses—Our outcome of interest was child's diagnostic group, with (ln-transformed) cytokines/chemokines as the predictors. We fitted separate models for each predictor and also examined multiple cytokines in one model. Covariates included child's age (hours) at blood spot collection, race/ethnicity, season of birth, gestational age (weeks), maternal allergies and asthma, years between sample collection and elution, cytokine/chemokine plate numbers, and frequency-matching variables: child's age at enrollment (months), sex, and regional center catchment area (5 geographic regions). All covariates were assessed for potential confounding by examining associations of each covariate with the predictor (cytokines/chemokines) and outcome (diagnostic group);

covariates broadly associated ($P < 0.20$) with at least the outcome included season of birth, gestational age, child's sex and age at study enrollment, and years between sample collection and elution. They were included in initial models, and a change of ~10% in β -coefficient of the predictor was used to determine which covariates remained in the model; final multinomial logistic regression models were adjusted for season of birth, gestational age, child's sex, and years between sample collection and elution. Odds ratios (OR) and 95% confidence intervals (CI) were calculated to measure the association between each analyte and a given diagnosis relative to a referent diagnosis. P -values were corrected for multiple comparisons (16 biomarkers) using the Benjamini-Hochberg procedure.(31)

Linear and Negative Binomial Regression Analyses—To further characterize ASD cases, we performed linear regression models adjusted for maternal education level (high school or less, some college, Bachelor degree or higher) to determine whether selected cytokines were associated with specific domains of cognitive (visual reception, receptive and expressive language) and adaptive (communication, socialization) development. Negative binomial regression models adjusted for maternal education and child's age at study visit were carried out to examine associations between selected cytokines and maladaptive behavior (irritability, lethargy, stereotypy, hyperactivity) counts while accounting for the overdispersed behavior scores. β -coefficients and standard errors (SE) were calculated to measure the association between each analyte and the expected value of either a developmental score (linear regression) or log count of behavior (negative binomial regression). Associations with P -values < 0.05 were considered significant and were corrected for multiple comparisons (5 developmental and 4 behavior scores).

RESULTS

Participants

TD controls were frequency-matched to ASD cases (4:1 male-to-female ratio) resulting in a skewed sex distribution and similar proportions of males in both groups (Table 1); 59% were male in the DD group, as they were not sex-matched. A higher proportion of TD was born in the Summer (39% vs. 24% and 30%) and fewer born in the Spring (14% vs. 24% and 22%) compared to cases and DD controls, respectively. Children with DD were born one to two weeks earlier, on average, than cases or TD controls (38 vs. 39 and 40 weeks, respectively). The length of time between blood spot collection and elution was approximately ½ year longer for cases than TD (7.8 vs. 7.4 years). There were also differences in regional catchment areas between cases and DD (33% vs. 59% were from Alta). Cases did not differ from TD or DD controls on race/ethnicity, age at blood spot collection or study enrollment, and maternal allergies and asthma. Also, cases and controls were similarly distributed across cytokine/chemokine plate numbers (Table S1).

Cytokine/Chemokine Distributions

Cytokine/chemokine concentrations measured in blood spots are shown in Table 2. Most analytes (11 of 17) were detectable in $> 75\%$ of samples; IL-4, IL-5, and IL-13 were detectable in 60-70% of samples; MIP-1 α and IL-6 were detected in 50% and 44% of samples, respectively. Eotaxin was detectable in only 10% of the samples and was excluded

from analyses. Overall, the percentage of samples that fell below levels of detection (LOD) of a given immune biomarker was evenly distributed between cases and controls; one exception was IL-4 (<LOD in 37% cases vs. 45% TD controls), indicating that TD controls, on average, had lower concentrations of IL-4 than ASD cases. Values <LOD were imputed by multiple imputation methods described earlier.

Cytokine/Chemokine Profiles

All immune biomarkers, except Eotaxin, were included in the initial PCA to examine global cytokine/chemokine expression patterns in cases and controls; three components were generated, each explaining 10% of the total variance of the analytes. However, MCP-1 and IP-10 did not correlate with these components (loadings <0.40) and were excluded from the subsequent PCA. The final PCA, with 14 immune biomarkers, produced three components that collectively explained 67% of the total variance (Table S2). Component 1 consisted of cytokines largely associated with adaptive immune responses (IL-2, IL-4, IL-5, IL-12, IL-13, IFN- γ , TNF- α); Component 2 included chemokines (MIP-1 α , MIP-1 β , RANTES, IL-8); and Component 3 included pro-inflammatory cytokines IL-1 β and IL-6, and the anti-inflammatory cytokine IL-10. Overall, plots of the principal component scores showed similar distributions across diagnostic groups with no overt clustering patterns that were predictive of case status (Figure S2).

Cytokines/Chemokines and Diagnosis

First, we conducted multinomial logistic regression models adjusted for season of birth, gestational age, child's sex, and years between sample collection and analysis to determine whether the concentrations of individual cytokines/chemokines were associated with ASD, irrespective of symptom severity, relative to DD and TD. Levels of (ln-transformed) IL-1 β and IL-4 were elevated in ASD compared with TD but did not reach statistical significance after multiple comparison correction (Table S3). No other cytokines/chemokines differed significantly between ASD and DD groups or between DD and TD controls.

Next, we examined ASD cases as two groups, defined by symptom intensity, in relation to each other and to TD and DD controls in models adjusted for the same covariates. Interestingly, elevated levels of IL-1 β (OR=0.45, 95% CI 0.25, 0.82) and several other pro-inflammatory cytokines/chemokines were associated with lower odds of severe ASD (ASD_{sev}) compared with mild-to-moderate ASD (ASD_{mild}) (Table 3). IL-1 β (OR=3.03, 95% CI 1.48, 6.23) was also associated with an increased likelihood of ASD_{mild} relative to TD. Conversely, elevated IL-4 was associated with increased odds of ASD_{sev} vs. TD but not statistically significant after multiple comparisons correction. No cytokines/chemokines differed significantly between the two case groups (ASD_{sev} and ASD_{mild}) and DD controls (Table S4).

When IL-1 β , IL-2, IL-4, IL-6, IFN- γ , and IP-10 were modeled together and adjusted for covariates, only IL-1 β and IL-4 emerged as independently associated with ASD_{mild} and ASD_{sev}, respectively, relative to TD and each other (Model 1, Table 4). We then retained only IL-1 β , IL-4, and covariates (Model 2); Relative to TD controls, elevated IL-1 β was associated with a 3-fold increased likelihood of ASD_{mild} (OR=3.02, 95% CI 1.43, 6.38)

while IL-4 was associated a 1.4-fold increased likelihood of ASD_{sev} (OR=1.40, 95% CI 1.03, 1.91). Compared with ASD_{mild}, IL-1 β associated with lower odds of ASD_{sev} (OR=0.37, 95% CI 0.20, 0.67) whereas IL-4 associated with higher odds of ASD_{sev} (OR=1.35, 95% CI 1.04, 1.75).

Selected Cytokines and Autism Severity, Behavior, and Development –Linear Regression

We examined whether neonatal IL-1 β and IL-4 concentrations were associated with any particular developmental or behavioral patterns assessed at age 2-5 years. The developmental scores (MSEL, VABS) were individually modeled using linear regression restricted to cases and adjusted for maternal education level, with both IL-1 β and IL-4 as the predictors. Neonatal IL-1 β concentrations were positively associated with MSEL visual reception (β =7.13, SE=2.54, P =0.01) and receptive language (language comprehension; β =8.32, SE=2.90, P =0.01), indicating better performance; conversely, IL-4 concentrations were negatively associated with MSEL visual reception, but this association was not significant after multiple comparisons adjustment (Figure 1, Table S5). One should note that the mean developmental quotients (DQ) on all MSEL scales for both case groups were well below cutoffs for typical cognitive function (DQ <70; i.e., >2 standard deviations below the mean of 100).

The magnitude of the associations between IL-1 β and MSEL visual reception (β = 7.97, SE=2.66, P =0.01) and receptive language subscales (β = 9.64, SE=3.03, P =0.01) was augmented when we examined male cases only (Figure S3, Table S6). Additionally, IL-4 levels were now significantly negatively associated with visual reception (β = -3.63, SE=1.33, P =0.04). No other behavioral or developmental scores associated with IL-1 β or IL-4 concentrations. Among controls (DD+TD), there was a trend suggesting an association between higher IL-1 β levels and lower MSEL expressive language (language production) (Figure S4, Table S7). IL-4 was not associated with any developmental domains.

DISCUSSION

The current study explores whether early cytokine/chemokine profiles are predictive of ASD. Elevated neonatal IL-4 and IL-1 β concentrations measured in blood spots collected within 48 hours of birth were independently associated with ASD relative to TD controls. IL-1 β levels were associated with a 3-fold increased likelihood of ASD with mild to moderately severe symptoms, while elevated IL-4 levels were associated with a 1.4-fold increase in the likelihood of severe ASD. IL-4 levels were also higher in children with severe ASD compared to those with mild-to-moderate ASD symptoms. We did not observe any significant differences in the levels of cytokines/chemokines between ASD cases and DD controls, although the DD sample size was likely too small to make definitive conclusions at this time. Among children with ASD, increased neonatal IL-4 concentrations were associated with greater impairments in non-verbal cognitive ability and language comprehension, particularly in male cases, but not in TD or DD controls.

The neonatal immune system is extremely immature, and cytokine production is much lower than in adults.(32) This was accurately reflected by the number of subjects whose whole blood cytokine levels were near or below the limit of detection. We expect the majority of

the analytes we measured to be of neonatal origin because maternal cytokines and chemokines are largely blocked from placental passage, with the possible exception of IL-6 and GM-CSF.(33, 34)

Neonatal blood spots have been used to measure cytokine profiles in several studies,(35, 36) and to identify immune markers for a variety of disorders, including type 1 diabetes,(37) toxoplasmosis,(38) Down syndrome, and ASD.(18-20, 39) A 2006 study by Nelson *et al.* measured cytokine levels in neonatal blood spots from children with ASD, though only IL-8 was within the detectable range. The current study utilized a highly optimized procedure capable of detecting extremely low levels of 17 cytokines/chemokines. In a similar study, Abdallah *et al.*(19) reported decreased levels of many cytokines among children with ASD, including IFN- γ , IL-2, IL-4, IL-6, and IL-1 β . While there were several analytes that overlapped between our study and that of Abdallah *et al.*, the methodology and analysis differed significantly. One major limitation of the Abdallah study was that the diagnoses of cases and controls were not confirmed clinically by standardized measures. In the current study, we had access to detailed behavioral and developmental characteristics of our participants. This proved to be especially important as the severity of ASD symptoms associated with cytokine levels. Our cytokine measurement methods differed slightly from Abdallah *et al.* as well; we corrected cytokine levels based on total protein content to account for differences in collection efficiency between samples, while Abdallah *et al.* assumed that each dried blood spot contained the same volume of blood. The study by Zerbo *et al.*(20) had similar limitations as the Abdallah study. Further, the assays used for the Zerbo study were not as sensitive as those used for the current study.

IL-1 β , IL-4, and their receptors are expressed in the developing brain,(40-43) and they have been shown to impact aspects of neuronal and glial cell development and function in cell culture models.(44) IL-1 β is an inflammatory cytokine produced by many cell types early during an immune response. Beyond its role in inflammation, IL-1 β has extensive neurological significance. It is capable of crossing the blood brain barrier and is involved in fever and sickness behavior.(45-47) Furthermore, genes for IL-1 β and its receptor-associated proteins have been associated with cognitive disabilities, schizophrenia, and ASD.(48-50) Elevated IL-1 β has been previously reported in older children with ASD as well.(12, 51-54)

IL-4 is a cytokine largely produced by T-helper type 2 (Th2) cells. It is involved in shaping the adaptive immune response, and is often associated with parasite defense, asthma, and atopy. IL-4 has been shown to impact neuronal proliferation, differentiation, survival, and synapse formation(55-58). Elevated IL-4 has also been linked to ASD with increased levels reported in maternal serum during the second trimester of pregnancy(59), and in amniotic fluid (60) collected from mothers giving birth to a child later diagnosed with ASD.

The increase in IL-1 β and IL-4 is likely reflective of a prenatal immune challenge. At birth, the immune system is skewed towards a Th2, or more regulatory phenotype (versus an inflammatory T-helper type 1 (Th1) phenotype), compared to adults(61, 62). Prenatal immune activation can impact many aspects of fetal development and is associated with adverse outcomes including preterm birth, cerebral palsy, and miscarriage.(63-66) More subtly, maternal atopic disorders such as asthma and allergy as well as increased IL-4 and

IFN- γ during pregnancy have been shown to be associated with an increased risk of ASD. (10, 67, 68) While many studies have examined the maternal gestational immune profile, newborn blood spots are primarily reflective of the infant's immune status. Early immune dysregulation in the infant may have an impact on the developing nervous system as well. Of particular interest were our findings that demonstrated an improvement in the visual reception and receptive language scores with elevated IL-1 β at birth, while these same scores were negatively associated with IL-4 levels in children with ASD. This apparent dichotomous finding suggests that skewing of the early immune environment towards a Th2 (IL-4 producing) phenotype could negatively impact the developmental trajectory of visual reception and receptive language while an increase in an opposing inflammatory cytokine associated with innate immune cell (and microglial) function alternatively protects or enhances these domains. Further mechanistic studies would need to be conducted to fully define the role of these two cytokines in this specific area of neurodevelopment.

It is of course possible that peripheral cytokine levels do not alter neurodevelopmental outcome independent of other factors. The immune and central nervous systems share many genes and signaling pathways, so disruption in one system can be reflected in the other. Altered cytokine profiles might simply be an epiphenomenon of genetic and/or environmental factors that impact neurodevelopment. Our data suggest, however, that a very early alteration in cytokine regulation is associated with a subsequent diagnosis of ASD. Ongoing studies will further address the relationship between neonatal cytokine profiles and immune disorders in children with ASD.

Collectively, our observations suggest that immune factors measured at birth could provide early markers of aberrant neurodevelopmental changes associated with ASD. Further, we demonstrate that differences in early neonatal cytokine profiles relate to ASD severity, which suggests that behavioral subphenotypic differences in the ASD population might have an immunologic component. In particular, the finding that the same cytokines are associating with both ASD risk and cognitive developmental outcomes (in the same or opposite directions) suggests a more global impact of early cytokine dysregulation. Finally, continued efforts to identify early markers of ASD will lead to a greater understanding of the disorder, and may ultimately suggest therapeutic options to improve the developmental trajectory and quality of life for affected individuals and their families.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

ACKNOWLEDGMENTS

This research was supported by the National Institutes of Health (P01 ES11269 and R01 ES015359), the U.S. Environmental Protection Agency through the Science to Achieve Results (STAR) program (R829388 and R833292) and by the MIND Institute, University of California, Davis. The authors would like to thank the CHARGE Study participants and staff for their dedication and effort.

REFERENCES

1. Lord C, Cook EH, Leventhal BL, Amaral DG. Autism spectrum disorders. *Neuron*. 2000; 28:355–363. [PubMed: 11144346]
2. World Health Organization. International Statistical Classification of Diseases and Related Health Problems (ICD-10). 10th edition 2006.
3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). 5th ed. American Psychiatric Association; Arlington, VA: 2013.
4. Herbert MR. Contributions of the environment and environmentally vulnerable physiology to autism spectrum disorders. *Curr Opin Neurol*. 2010; 23:103–110. [PubMed: 20087183]
5. Le Couteur A, Haden G, Hammal D, McConachie H. Diagnosing autism spectrum disorders in pre-school children using two standardised assessment instruments: the ADI-R and the ADOS. *J Autism Dev Disord*. 2008; 38:362–372. [PubMed: 17605097]
6. Lord C, Risi S, Lambrecht L, Cook EH Jr, Leventhal BL, DiLavore PC, et al. The autism diagnostic observation schedule-generic: a standard measure of social and communication deficits associated with the spectrum of autism. *J Autism Dev Disord*. 2000; 30:205–223. [PubMed: 11055457]
7. Lord C, Rutter M, Le Couteur A. Autism Diagnostic Interview-Revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. *J Autism Dev Disord*. 1994; 24:659–685. [PubMed: 7814313]
8. Dawson G, Jones EJ, Merkle K, Venema K, Lowy R, Faja S, et al. Early behavioral intervention is associated with normalized brain activity in young children with autism. *J Am Acad Child Adolesc Psychiatry*. 2012; 51:1150–1159. [PubMed: 23101741]
9. Goines, P., Croen, LA., Braunschweig, D., Yoshida, C., Grether, J., Hansen, R., Kharrazi, M., Ashwood, P., Van de Water, J. Increased mid-gestational IFN- γ , IL-4, and IL-5 in women giving birth to a child with autism: a case-control study. *Molecular Autism*-submitted. 2011.
10. Croen LA, Braunschweig D, Haapanen L, Yoshida CK, Fireman B, Grether JK, et al. Maternal mid-pregnancy autoantibodies to fetal brain protein: the early markers for autism study. *Biol Psychiatry*. 2008; 64:583–588. [PubMed: 18571628]
11. Careaga M, Van de Water J, Ashwood P. Immune dysfunction in autism: a pathway to treatment. *Neurotherapeutics*. 2010; 7:283–292. [PubMed: 20643381]
12. Ashwood P, Krakowiak P, Hertz-Picciotto I, Hansen R, Pessah I, Van de Water J. Elevated plasma cytokines in autism spectrum disorders provide evidence of immune dysfunction and are associated with impaired behavioral outcome. *Brain Behav Immun*. 2011; 25:40–45. [PubMed: 20705131]
13. Onore C, Enstrom A, Krakowiak P, Hertz-Picciotto I, Hansen R, Van de Water J, et al. Decreased cellular IL-23 but not IL-17 production in children with autism spectrum disorders. *J Neuroimmunol*. 2009; 216:126–129. [PubMed: 19800697]
14. Wills S, Cabanlit M, Bennett J, Ashwood P, Amaral D, Van de Water J. Autoantibodies in autism spectrum disorders (ASD). *Ann N Y Acad Sci*. 2007; 1107:79–91. [PubMed: 17804535]
15. Goines P, Haapanen L, Boyce R, Duncanson P, Braunschweig D, Delwiche L, et al. Autoantibodies to cerebellum in children with autism associate with behavior. *Brain Behav Immun*. 2011; 25:514–523. [PubMed: 21134442]
16. Singer HS, Morris CM, Williams PN, Yoon DY, Hong JJ, Zimmerman AW. Antibrain antibodies in children with autism and their unaffected siblings. *J Neuroimmunol*. 2006; 178:149–155. [PubMed: 16842863]
17. Goines PE, Ashwood P. Cytokine dysregulation in autism spectrum disorders (ASD): possible role of the environment. *Neurotoxicol Teratol*. 2013; 36:67–81. [PubMed: 22918031]
18. Abdallah MW, Larsen N, Grove J, Bonefeld-Jorgensen EC, Norgaard-Pedersen B, Hougaard DM, et al. Neonatal chemokine levels and risk of autism spectrum disorders: findings from a Danish historic birth cohort follow-up study. *Cytokine*. 2013; 61:370–376. [PubMed: 23267761]
19. Abdallah MW, Larsen N, Mortensen EL, Atladottir HO, Norgaard-Pedersen B, Bonefeld-Jorgensen EC, et al. Neonatal levels of cytokines and risk of autism spectrum disorders: an exploratory register-based historic birth cohort study utilizing the Danish Newborn Screening Biobank. *J Neuroimmunol*. 2012; 252:75–82. [PubMed: 22917523]

20. Zerbo O, Yoshida C, Grether JK, Van de Water J, Ashwood P, Delorenze GN, et al. Neonatal cytokines and chemokines and risk of Autism Spectrum Disorder: the Early Markers for Autism (EMA) study: a case-control study. *J Neuroinflammation*. 2014; 11:113. [PubMed: 24951035]
21. Hertz-Picciotto I, Croen LA, Hansen R, Jones CR, van de Water J, Pessah IN. The CHARGE study: an epidemiologic investigation of genetic and environmental factors contributing to autism. *Environ Health Perspect*. 2006; 114:1119–1125. [PubMed: 16835068]
22. Mullen, EM. *Mullen Scales of Early Early Learning*. American Guidance Service, Inc; Circle Pines, MN: 1995.
23. Sparrow, SS., Balla, DA., Cicchetti, DV. *Vineland Adaptive Behavior Scales Interview Edition Expanded from Manual*. American Guidance Services, Inc; Circle Pines, MN: 1984.
24. Le Couteur, A., Lord, C., Rutter, M. *Autism Diagnostic Interview–Revised (ADI-R)*. Western Psychological Services; Los Angeles, CA: 2003.
25. Lord, C., Rutter, M., DiLavore, PC., Risi, S., Gotham, K., Bishop, SL. *Autism Diagnostic Observation Schedule, Second Edition (ADOS-2)*. Western Psychological Services; Los Angeles, CA: 2012.
26. Risi S, Lord C, Gotham K, Corsello C, Chrysler C, Szatmari P, et al. Combining information from multiple sources in the diagnosis of autism spectrum disorders. *J Am Acad Child Adolesc Psychiatry*. 2006; 45:1094–1103. [PubMed: 16926617]
27. Rutter, M., Bailey, A., Berument, SK., Lord, C., Pickles, A. *Social Communication Questionnaire (SCQ)*. Western Psychological Services; Los Angeles, CA: 2003.
28. Aman, MG., Singh, NN. *Aberrant Behavior Checklist—Community*. Slosson Educational Publications; East Aurora, NY: 1994.
29. Kharrazi M, Pearl M, Yang J, DeLorenze GN, Bean CJ, Callaghan WM, et al. California Very Preterm Birth Study: design and characteristics of the population- and biospecimen bank-based nested case-control study. *Paediatr Perinat Epidemiol*. 2012; 26:250–263. [PubMed: 22471684]
30. Kabacoff, RI. *Determining the Dimensionality of Data: A SAS® Macro for Parallel Analysis*. Proceedings of the Twenty Eighth Annual SAS Users Group International (SUGI 28); Seattle, WA. 2003.
31. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. *J R Stat Soc Series B*. 1995; 57:289–300.
32. Jaspan HB, Lawn SD, Safrit JT, Bekker LG. The maturing immune system: implications for development and testing HIV-1 vaccines for children and adolescents. *AIDS*. 2006; 20:483–494. [PubMed: 16470112]
33. Zaretsky MV, Alexander JM, Byrd W, Bawdon RE. Transfer of inflammatory cytokines across the placenta. *Obstet Gynecol*. 2004; 103:546–550. [PubMed: 14990420]
34. Gregor H, Egarter C, Levin D, Sternberger B, Heinze G, Leitich H, et al. The passage of granulocyte-macrophage colony-stimulating factor across the human placenta perfused in vitro. *J Soc Gynecol Investig*. 1999; 6:307–310.
35. Skogstrand K, Thorsen P, Norgaard-Pedersen B, Schendel DE, Sorensen LC, Hougaard DM. Simultaneous measurement of 25 inflammatory markers and neurotrophins in neonatal dried blood spots by immunoassay with xMAP technology. *Clin Chem*. 2005; 51:1854–1866. [PubMed: 16081507]
36. Skogstrand K, Ekelund CK, Thorsen P, Vogel I, Jacobsson B, Norgaard-Pedersen B, et al. Effects of blood sample handling procedures on measurable inflammatory markers in plasma, serum and dried blood spot samples. *J Immunol Methods*. 2008; 336:78–84. [PubMed: 18495149]
37. Eising S, Svensson J, Skogstrand K, Nilsson A, Lynch K, Andersen PS, et al. Type 1 diabetes risk analysis on dried blood spot samples from population-based newborns: design and feasibility of an unselected case-control study. *Paediatr Perinat Epidemiol*. 2007; 21:507–517. [PubMed: 17937736]
38. Neto EC, Rubin R, Schulte J, Giugliani R. Newborn screening for congenital infectious diseases. *Emerg Infect Dis*. 2004; 10:1068–1073. [PubMed: 15207059]
39. Nelson PG, Kuddo T, Song EY, Dambrosia JM, Kohler S, Satyanarayana G, et al. Selected neurotrophins, neuropeptides, and cytokines: developmental trajectory and concentrations in

- neonatal blood of children with autism or Down syndrome. *Int J Dev Neurosci*. 2006; 24:73–80. [PubMed: 16289943]
40. Lovett-Racke AE, Smith ME, Arredondo LR, Bittner PS, Ratts RB, Shive CL, et al. Developmentally regulated gene expression of Th2 cytokines in the brain. *Brain Res*. 2000; 870:27–35. [PubMed: 10869498]
41. Sawada M, Itoh Y, Suzumura A, Marunouchi T. Expression of cytokine receptors in cultured neuronal and glial cells. *Neurosci Lett*. 1993; 160:131–134. [PubMed: 8247342]
42. Sawada M, Suzumura A, Marunouchi T. Cytokine network in the central nervous system and its roles in growth and differentiation of glial and neuronal cells. *Int J Dev Neurosci*. 1995; 13:253–264. [PubMed: 7572279]
43. Nolan Y, Maher FO, Martin DS, Clarke RM, Brady MT, Bolton AE, et al. Role of interleukin-4 in regulation of age-related inflammatory changes in the hippocampus. *The Journal of biological chemistry*. 2005; 280:9354–9362. [PubMed: 15615726]
44. de Araujo EG, da Silva GM, Dos Santos AA. Neuronal cell survival: the role of interleukins. *Ann N Y Acad Sci*. 2009; 1153:57–64. [PubMed: 19236328]
45. Banks WA, Ortiz L, Plotkin SR, Kastin AJ. Human interleukin (IL) 1 alpha, murine IL-1 alpha and murine IL-1 beta are transported from blood to brain in the mouse by a shared saturable mechanism. *The Journal of pharmacology and experimental therapeutics*. 1991; 259:988–996. [PubMed: 1762091]
46. Skurlova M, Stofkova A, Jurcovicova J. Exogenous IL-1beta induces its own expression, but not that of IL-6 in the hypothalamus and activates HPA axis and prolactin release. *Endocrine regulations*. 2006; 40:125–128. [PubMed: 17201586]
47. Dantzer R. Cytokine-induced sickness behavior: where do we stand? *Brain Behav Immun*. 2001; 15:7–24. [PubMed: 11259077]
48. Katila H, Hanninen K, Hurme M. Polymorphisms of the interleukin-1 gene complex in schizophrenia. *Molecular psychiatry*. 1999; 4:179–181. [PubMed: 10208450]
49. Piton A, Michaud JL, Peng H, Aradhya S, Gauthier J, Mottron L, et al. Mutations in the calcium-related gene IL1RAPL1 are associated with autism. *Human molecular genetics*. 2008; 17:3965–3974. [PubMed: 18801879]
50. Handley MT, Lian LY, Haynes LP, Burgoyne RD. Structural and functional deficits in a neuronal calcium sensor-1 mutant identified in a case of autistic spectrum disorder. *PLoS one*. 2010; 5:e10534. [PubMed: 20479890]
51. Suzuki K, Matsuzaki H, Iwata K, Kamen Y, Shimmura C, Kawai S, et al. Plasma cytokine profiles in subjects with high-functioning autism spectrum disorders. *PLoS one*. 2011; 6:e20470. [PubMed: 21647375]
52. Emanuele E, Orsi P, Boso M, Brogna D, Brondino N, Barale F, et al. Low-grade endotoxemia in patients with severe autism. *Neurosci Lett*. 2010; 471:162–165. [PubMed: 20097267]
53. Jyonouchi H, Sun S, Le H. Proinflammatory and regulatory cytokine production associated with innate and adaptive immune responses in children with autism spectrum disorders and developmental regression. *J Neuroimmunol*. 2001; 120:170–179. [PubMed: 11694332]
54. Enstrom AM, Onore CE, Van de Water JA, Ashwood P. Differential monocyte responses to TLR ligands in children with autism spectrum disorders. *Brain Behav Immun*. 2010; 24:64–71. [PubMed: 19666104]
55. Butovsky O, Ziv Y, Schwartz A, Landa G, Talpalar AE, Pluchino S, et al. Microglia activated by IL-4 or IFN-gamma differentially induce neurogenesis and oligodendrogenesis from adult stem/progenitor cells. *Molecular and cellular neurosciences*. 2006; 31:149–160. [PubMed: 16297637]
56. Araujo DM, Cotman CW. Trophic effects of interleukin-4, -7 and -8 on hippocampal neuronal cultures: potential involvement of glial-derived factors. *Brain Res*. 1993; 600:49–55. [PubMed: 8422590]
57. da Silva AG, Campello-Costa P, Linden R, Sholl-Franco A. Interleukin-4 blocks proliferation of retinal progenitor cells and increases rod photoreceptor differentiation through distinct signaling pathways. *J Neuroimmunol*. 2008; 196:82–93. [PubMed: 18378323]

58. Sholl-Franco A, Marques PM, Ferreira CM, de Araujo EG. IL-4 increases GABAergic phenotype in rat retinal cell cultures: involvement of muscarinic receptors and protein kinase C. *J Neuroimmunol.* 2002; 133:20–29. [PubMed: 12446004]
59. Goines PE, Croen LA, Braunschweig D, Yoshida CK, Grether J, Hansen R, et al. Increased midgestational IFN-gamma, IL-4 and IL-5 in women bearing a child with autism: A case-control study. *Molecular autism.* 2011; 2:13. [PubMed: 21810230]
60. Abdallah MW, Larsen N, Grove J, Norgaard-Pedersen B, Thorsen P, Mortensen EL, et al. Amniotic fluid inflammatory cytokines: Potential markers of immunologic dysfunction in autism spectrum disorders. *The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.* 2011
61. Zaghouni H, Hoeman CM, Adkins B. Neonatal immunity: faulty T-helpers and the shortcomings of dendritic cells. *Trends Immunol.* 2009; 30:585–591. [PubMed: 19846341]
62. Rose S, Lichtenheld M, Foote MR, Adkins B. Murine neonatal CD4+ cells are poised for rapid Th2 effector-like function. *J Immunol.* 2007; 178:2667–2678. [PubMed: 17312108]
63. Skogstrand K, Hougaard DM, Schendel DE, Bent NP, Svaerke C, Thorsen P. Association of preterm birth with sustained postnatal inflammatory response. *Obstet Gynecol.* 2008; 111:1118–1128. [PubMed: 18448744]
64. Minagawa K, Tsuji Y, Ueda H, Koyama K, Tanizawa K, Okamura H, et al. Possible correlation between high levels of IL-18 in the cord blood of pre-term infants and neonatal development of periventricular leukomalacia and cerebral palsy. *Cytokine.* 2002; 17:164–170. [PubMed: 11895335]
65. Lyon D, Cheng CY, Howland L, Rattican D, Jallo N, Pickler R, et al. Integrated review of cytokines in maternal, cord, and newborn blood: part I--associations with preterm birth. *Biol Res Nurs.* 2010; 11:371–376. [PubMed: 20034950]
66. Pickler R, Brown L, McGrath J, Lyon D, Rattican D, Cheng CY, et al. Integrated review of cytokines in maternal, cord, and newborn blood: part II-- associations with early infection and increased risk of neurologic damage in preterm infants. *Biol Res Nurs.* 2010; 11:377–386. [PubMed: 20028689]
67. Croen LA, Grether JK, Yoshida CK, Odouli R, Van de Water J. Maternal autoimmune diseases, asthma and allergies, and childhood autism spectrum disorders: a case-control study. *Archives of pediatrics & adolescent medicine.* 2005; 159:151–157. [PubMed: 15699309]
68. Lyall K, Ashwood P, Van de Water J, Hertz-Picciotto I. Maternal immune-mediated conditions, autism spectrum disorders, and developmental delay. *J Autism Dev Disord.* 2014; 44:1546–1555. [PubMed: 24337796]




Figure 1. Cognitive and adaptive scores of 2-5 year old children with ASD in relation to their neonatal IL-1β and IL-4 concentrations

This figure illustrates the mean change in cognitive and adaptive scores for a 1-unit increase in ln-transformed cytokine (pg/mg total protein). Bars with an asterisk (*) denote statistically significant associations ($P < 0.05$); P -values were adjusted for multiple comparisons. Mullen Scales of Early Learning (MSEL) measures cognitive development and subscales include Visual Reception (non-verbal cognitive ability), Receptive Language (language comprehension), and Expressive Language (language production); Vineland Adaptive Behavior Scales (VABS) subscales include Communication and Socialization. The scores have been converted to developmental quotients, and higher scores represent better performance.

Table 1

Participant demographic and clinical characteristics, N=303

	ASD (n=214)		DD (n=27)		TD (n=62)		P- value ^g
	n	%	n	%	n	%	
Sex ^a							0.0004
Male	189	88	16	59	50	81	
Female	25	12	11	41	12	19	
Race/Ethnicity							0.81
White	100	47	11	41	27	44	
Hispanic	71	33	11	41	25	40	
Other ^b	43	20	5	18	10	16	
Season of birth ^c							0.29
Winter	47	22	4	15	15	24	
Spring	50	24	6	22	9	14	
Summer	52	24	8	30	24	39	
Fall	65	30	9	33	14	23	
Maternal allergies or asthma ^d	90	45	10	42	26	46	0.95
Any allergy ^e	80	40	7	29	22	39	0.60
Environmental allergy	54	27	6	25	13	23	0.82
Asthma	24	12	4	17	10	18	0.50
Regional Center catchment area ^a							0.20
Alta, Far Northern, and Redwood Coast	70	33	16	59	26	42	
North Bay	27	13	0	0	8	13	
East Bay, San Andreas, and Golden Gate	25	12	1	4	6	10	
Valley Mountain, Central Valley, and Kern	31	14	4	15	8	13	
All Los Angeles, Orange, San Diego, Tri- counties, and Inland	61	28	6	22	14	22	

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

	Mean	SD	Range	Mean	SD	Range	Mean	SD	Range	P-value ^g
	ASD (n=214)			DD (n=27)			TD (n=62)			P-value ^g
	n	%		n	%		n	%		P-value ^g
Gestational age (weeks) ^f	39.3	1.8	31-45	38.2	3.4	30-43	39.9	1.6	35-45	0.001
Age (hours) at blood spot collection	29.3	9.9	3-48	29.5	10.2	13-47	28.6	8.2	13-47	0.88
Age (months) at study enrollment ^a	43.4	10.0	24-65	45.3	9.5	24-58	40.8	8.6	26-60	0.08
Years between collection and elution	7.8	1.4	4.7-10.7	7.6	1.2	4.9-9.5	7.4	1.3	4.8-9.9	0.13

^aTD controls were frequency-matched to a projected distribution of ASD cases on age, sex, and regional center catchment area

^bIncludes Black/African American, American Indian/Alaska Native, Asian, Pacific Islander/Native Hawaiian, Multi-racial

^cMonths grouped by season as follows: Winter = December to February, Spring = March to May, Summer = June to August, Fall = September to November

^d22 participants were missing maternal allergies/asthma (14 ASD, 3 DD, 5 TD)

^eAllergies include the following types: environmental (e.g., seasonal, pet, mold), food, skin, medication, or other

^f7 participants were missing gestational age (5 ASD, 2 TD)

^gP-values for categorical and continuous variables calculated with Chi-square test and one-way analysis of variance (ANOVA), respectively

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 2
Median concentrations and ranges of cytokines and chemokines in eluted blood spots, N=303

Cytokine ^a	Range ^b	ASD (n=214)			DD (n=27)			TD (n=62)		
		Med	IQR	<LOD	Med	IQR	<LOD	Med	IQR	<LOD
IL-1 β	0.03 – 2.03	0.31	0.23 – 0.40	--	0.32	0.27 – 0.46	--	0.28	0.20 – 0.38	--
IL-2	0.04 – 9.75	1.14	0.29 – 2.30	14.5%	1.22	0.21 – 1.91	14.8%	1.13	0.19 – 2.00	16.1%
IL-4	0.01 – 1.38	0.04	<lod – 0.07	37.4%	0.05	<lod – 0.07	25.9%	0.04	<lod – 0.08	45.2%
IL-5	0.03 – 7.81	0.40	<lod – 0.74	29.4%	0.36	<lod – 0.50	25.9%	0.44	<lod – 0.66	29.0%
IL-6	0.01 – 585.2	<lod	<lod – 1.46	56.1%	<lod	<lod – 1.80	59.3%	<lod	<lod – 0.45	54.8%
IL-10	0.01 – 4.93	0.19	0.04 – 0.37	20.1%	0.29	0.06 – 0.42	18.5%	0.24	<lod – 0.45	27.4%
IL-12	0.01 – 213.3	0.27	0.19 – 0.37	0.9%	0.23	0.16 – 0.36	--	0.25	0.17 – 0.36	4.8%
IL-13	0.01 – 2.26	0.05	<lod – 0.13	38.3%	0.10	0.01 – 0.21	22.2%	0.05	<lod – 0.14	40.3%
IFN- γ	0.01 – 5.86	0.25	0.13 – 0.38	8.4%	0.18	0.12 – 0.31	3.7%	0.23	0.06 – 0.38	16.1%
TNF- α	0.01 – 0.84	0.08	0.05 – 0.12	5.6%	0.10	0.05 – 0.13	3.7%	0.10	0.05 – 0.13	4.8%
IL-8	4.26 – 356.5	18.22	12.59 – 27.94	--	22.01	12.01 – 36.05	--	22.24	12.51 – 30.22	--
MCP-1	9.75 – 523.1	104.6	109.0 – 192.1	--	126.7	96.48 – 156.1	--	155.7	114.2 – 207.6	--
MIP-1 α	0.35 – 437.8	1.25	<lod – 3.11	48.6%	<lod	<lod – 3.11	51.9%	<lod	<lod – 3.11	54.8%
MIP-1 β	1.17 – 24.44	5.89	3.91 – 7.54	--	5.49	3.91 – 7.37	--	5.31	3.88 – 7.44	--
Eotaxin	1.30 – 12.11	<lod	<lod – <lod	89.7%	<lod	<lod – <lod	92.6%	<lod	<lod – <lod	88.7%
IP-10	0.12 – 118.6	6.96	4.70 – 10.67	--	5.88	4.75 – 9.45	--	6.85	4.99 – 9.45	--

Cytokine ^a	ASD (n=214)			DD (n=27)			TD (n=62)			
	Range ^b	Med	IQR	<LOD	Med	IQR	<LOD	Med	IQR	<LOD
RANTES	493.1 – 21244	1951	1434 - 2500	--	1653	1108 - 2440	--	1810	1492 - 2278	--

Abbreviations: Med = Median, IQR = Interquartile range, LOD = Level of detection; IL = interleukin, IFN = interferon, TNF = tumor necrosis factor, MCP = monocyte chemoattractant protein, MIP = macrophage inflammatory protein, IP = interferon-gamma induced protein, RANTES = regulated on activation normal T-cell expressed and secreted

^aCytokine and chemokine concentrations are presented in pg/ml eluate (not corrected for total protein)

^bRange of detected values in the study population

Table 3

Adjusted odds ratios comparing neonatal cytokine and chemokine concentrations in ASD with severe symptoms, ASD with mild to moderate symptoms, and TD, N=276^a

Cytokine or Chemokine	ASD _{sev} vs. ASD _{mild}			ASD _{sev} vs. TD			ASD _{mild} vs. TD		
	OR	95% CI	P-value ^b	OR	95% CI	P-value ^b	OR	95% CI	P-value ^b
IL-1β	0.45	(0.25, 0.82)	0.0459	1.37	(0.75, 2.49)	0.8773	3.03	(1.48, 6.23)	0.0416
IL-2	1.10	(0.91, 1.31)	0.5708	1.21	(0.99, 1.47)	0.4792	1.10	(0.89, 1.37)	0.6011
IL-4	1.14	(0.90, 1.44)	0.5708	1.39	(1.04, 1.85)	0.4048	1.22	(0.89, 1.68)	0.4362
IL-5	1.02	(0.83, 1.24)	0.9414	1.06	(0.86, 1.31)	0.9027	1.05	(0.82, 1.33)	0.7637
IL-6	0.86	(0.77, 0.96)	0.0459	0.94	(0.84, 1.07)	0.8773	1.10	(0.96, 1.26)	0.3934
IL-10	0.90	(0.75, 1.10)	0.5708	0.98	(0.80, 1.21)	0.9404	1.09	(0.86, 1.38)	0.6484
IL-12	0.93	(0.69, 1.26)	0.8673	1.29	(0.93, 1.81)	0.6976	1.39	(0.95, 2.04)	0.2947
IL-13	0.98	(0.79, 1.21)	0.9414	1.05	(0.84, 1.32)	0.9027	1.07	(0.83, 1.39)	0.6917
IFN-γ	0.74	(0.58, 0.95)	0.0820	1.11	(0.88, 1.39)	0.8773	1.49	(1.11, 2.00)	0.0648
TNF-α	1.00	(0.71, 1.42)	0.9895	1.12	(0.77, 1.64)	0.9027	1.12	(0.73, 1.72)	0.6917
IL-8	0.87	(0.59, 1.27)	0.7424	1.15	(0.72, 1.83)	0.9027	1.32	(0.79, 2.20)	0.5024
MCP-1	0.96	(0.57, 1.62)	0.9414	0.87	(0.49, 1.54)	0.9027	0.90	(0.47, 1.74)	0.7637
MIP-1α	0.94	(0.79, 1.12)	0.7476	1.02	(0.84, 1.24)	0.9313	1.08	(0.87, 1.35)	0.6484
MIP-1β	0.67	(0.39, 1.16)	0.4957	1.10	(0.58, 2.06)	0.9313	1.63	(0.81, 3.28)	0.3934
IP-10	0.57	(0.37, 0.86)	0.0459	1.01	(0.65, 1.59)	0.9502	1.79	(1.06, 3.02)	0.1541
RANTES	0.73	(0.45, 1.17)	0.5133	1.33	(0.72, 2.46)	0.8773	1.82	(0.93, 3.55)	0.2947

^aLogistic regression models were adjusted for season of birth, gestational age, years from blood spot collection to elution, and child's sex; cytokines/chemokines were ln-transformed and normalized for total protein (pg/mg total protein); values below levels of detection were imputed by

multiple imputation; 276 participants comprised the following groups: 141 ASD (severe), 73 ASD (mild), and 62 TD; ASD severity was defined using ADOS comparison scores, where ≥ 7 indicated severe and <7 indicated mild to moderate symptoms; OR = adjusted odds ratio, CI = confidence interval

^b *P*-values were corrected for multiple comparisons (16 biomarkers)

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 4

Adjusted odds ratios comparing neonatal cytokine and chemokine concentrations in ASD with severe symptoms, ASD with mild to moderate symptoms, and TD in one model, N=276^a

Cytokine or Chemokine	ASD _{sev} vs. ASD _{mild}			ASD _{sev} vs. TD			ASD _{mild} vs. TD		
	OR	95% CI	P-value	OR	95% CI	P-value	OR	95% CI	P-value
<i>Model 1:</i>									
IL-1β	0.59	(0.29, 1.21)	0.15	1.44	(0.68, 3.04)	0.34	2.43	(0.99, 5.96)	0.05
IL-4	1.44	(1.08 , 1.91)	0.01	1.39	(1.00 , 1.93)	0.05	0.96	(0.67, 1.39)	0.84
IL-6	0.92	(0.81, 1.04)	0.19	0.90	(0.78, 1.04)	0.17	0.99	(0.84, 1.15)	0.85
IFN-γ	0.76	(0.57, 1.01)	0.06	0.99	(0.75, 1.30)	0.92	1.30	(0.94, 1.81)	0.12
IP-10	0.69	(0.43, 1.10)	0.11	1.05	(0.64, 1.71)	0.85	1.52	(0.86, 2.68)	0.15
<i>Model 2:</i>									
IL-1β	0.37	(0.20 , 0.67)	0.001	1.10	(0.59, 2.07)	0.76	3.02	(1.43 , 6.38)	0.004
IL-4	1.35	(1.04 , 1.75)	0.02	1.40	(1.03 , 1.91)	0.03	1.04	(0.74, 1.46)	0.83

^a Logistic regression model included selected cytokines/chemokines modeled together and was adjusted for season of birth, gestational age, years from blood spot collection to elution, and child's sex; cytokines/chemokines were ln-transformed and normalized for total protein (pg/mg total protein); values below levels of detection were imputed by multiple imputation; 276 participants comprised the following groups: 141 ASD (severe), 73 ASD (mild), and 62 TD; ASD severity was defined using ADOS comparison scores, where ≥ 7 indicated severe and <7 indicated mild to moderate symptoms; OR = adjusted odds ratio, CI = confidence interval